Recombinant Human Oncostatin M/OSM Protein

Oncostatin M (OSM) is a member of the interleukin-6 (IL-6) cytokine family, playing a crucial role in various physiological and pathological processes, including inflammation, tissue repair, and tumor progression. OSM is produced by a variety of cell types, including T cells, monocytes, and synovial fibroblasts, and exerts its effects by signaling through the glycoprotein 130 receptor complex, which is shared with other cytokines like IL-6 and leukemia inhibitory factor (LIF). Research demonstrates that OSM is involved in bone metabolism, promoting osteoblast differentiation and inhibiting osteoclastogenesis, thus influencing conditions like osteoporosis and metastatic bone disease. Moreover, OSM has been implicated in the pathogenesis of various diseases, including cancer, rheumatoid arthritis, and cardiovascular disorders, making it a potential therapeutic target. The development of recombinant OSM proteins has facilitated detailed studies of its biological functions and therapeutic applications, fostering a greater understanding of its role in disease modulation. Advances in recombinant DNA technology have also enabled the production of OSM with improved stability and biological activity, paving the way for innovative treatments based on this cytokine. Thus, ongoing research on OSM and its recombinant forms is vital for elucidating their therapeutic potential in targeting inflammation and tumorigenesis, highlighting the importance of this cytokine in both research and clinical settings.